文献速递瘢痕与激光

DPP-4抑制剂降低糖尿病患者胸骨正中切开术后增生性瘢痕与瘢痕疙瘩风险:日本全国回顾性队列研究

Dipeptidyl Peptidase-4 Inhibitor Reduces the Risk of Developing Hypertrophic Scars and Keloids following Median Sternotomy in Diabetic Patients: A Nationwide Retrospective Cohort Study Using the National Database of Health Insurance Claims of Japan.
PubMed 文献 · Plast Reconstr Surg · 2020-01-01

该研究利用日本全国健康保险理赔数据库2013年4月至2015年3月数据,纳入5430例接受胸骨正中切开术的患者,比较使用与未使用二肽基肽酶-4(DPP-4)抑制剂者术后增生性瘢痕或瘢痕疙瘩的发生风险。结果显示DPP-4抑制剂治疗组发生风险显著更低(p=0.04),提示其可能抑制术后瘢痕形成。

要点

  • 胸骨正中切开术后,DPP-4抑制剂治疗组增生性瘢痕或瘢痕疙瘩发生风险显著低于未治疗组(p=0.04)。
  • 治疗组446例中发生增生性瘢痕或瘢痕疙瘩者少于10例(<2%),未治疗组4984例中为152例(3.05%)。
  • 研究为回顾性队列研究,证据等级为治疗性III级,需进一步前瞻性研究验证。

核心结论

  • DPP-4抑制剂可抑制糖尿病患者胸骨正中切开术后增生性瘢痕或瘢痕疙瘩的发生。

研究设计与样本

  • 回顾性队列研究,数据来源于日本全国健康保险理赔与特定健康检查数据库2013年4月至2015年3月。
  • 纳入基于理赔手术代码接受胸骨正中切开术的患者5430例(男3509例,女1921例)。
  • 使用DPP-4抑制剂者为治疗组(446例),未使用者为非治疗组(4984例)。

主要发现

  • 治疗组446例中发生增生性瘢痕或瘢痕疙瘩者少于10例(<2%)。
  • 非治疗组4984例中152例(3.05%)发生增生性瘢痕或瘢痕疙瘩。
  • 治疗组风险显著低于非治疗组(p=0.04)。
  • 采用逻辑回归分析调整混杂因素,以增生性瘢痕形成史为解释变量。

临床怎么用

  • 对于接受胸骨正中切开术的糖尿病患者,使用DPP-4抑制剂可能有助于降低术后增生性瘢痕或瘢痕疙瘩风险。

局限性

  • 研究为回顾性队列设计,证据等级为治疗性III级,可能存在未完全校正的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertrophic scars and keloids, which are abnormalities of fibrosis, often occur in surgical wounds; however, their exact cause and preventive measures are unknown. The administration of dipeptidyl peptidase-4 inhibitors to humans is expected to suppress fibrosis in wounds and minimize hypertrophic scar and keloid formation. METHODS: This study aimed to verify the suppressive effect of dipeptidyl peptidase-4 inhibitors on the formation of hypertrophic scars or keloids using real world data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. It is a retrospective cohort study, and data were extracted from the National Database between April of 2013 and March of 2015. Patients who underwent median sternotomy were included in the study based on their claimed surgical codes. Subjects who were prescribed dipeptidyl peptidase-4 inhibitors constituted the treatment group; subjects who were not prescribed or administered dipeptidyl peptidase-4 inhibitors during that period constituted the nontreatment group. RESULTS: Subjects included 5430 patients throughout Japan (3509 men and 1921 women). Of the 446 subjects who were treated with dipeptidyl peptidase-4 inhibitors within 1 year before the procedure, fewer than 10 (<2 percent) developed either hypertrophic scars or keloids. Of the 4984 subjects who were not treated, 152 (3.05 percent) were at significantly lower risk for hypertrophic scars and keloids (p = 0.04). A logistic regression analysis was performed to adjust for confounding factors, with history of hypertrophic scar formation as the explained variable. CONCLUSION: This study revealed that dipeptidyl peptidase-4 inhibitors suppress the onset of hypertrophic scars or keloids after surgery in humans. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Suwanai H, Watanabe R, Sato M, et al. Dipeptidyl Peptidase-4 Inhibitor Reduces the Risk of Developing Hypertrophic Scars and Keloids following Median Sternotomy in Diabetic Patients: A Nationwide Retrospective Cohort Study Using the National Database of Health Insurance Claims of Japan. Plast Reconstr Surg. 2020. PMID: 32590649. doi:10.1097/PRS.0000000000006904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。